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Platelet-Mediated Thrombosis in Stenosed Canine Coronary Arteries:
Inhibition by Nicergoline, a Platelet-Active
Alpha-Adrenergic Antagonist
ROBERTO BOLLI, MD, J. ANTHONY WARE, MD, TEDD A. BRANDON, BS,
DONALD G. WEILBAECHER, MD, MYLES L. MACE, JR., PHD
Houston. Texas
The effects of nicergoline, anew agent that blocks alpha-
adrenergic receptors and inhibits platelet phospholipase,
were evaluated in a canine model of platelet-mediated
coronary thrombosis. In 48 open chest dogs, the circum-
flex coronary artery was stenosed by plicating the artery
wall with a suture. Thirty-four of the 48 dogs exhibited
cyclic reductions in flow in the stenotic vessel, followed
by a sudden return to control levels. The reductions in
flow were unabated in all but two dogs after heparin
administration (1,000 U/kg per h), unaffected by large
doses of nitroglycerin and nifedipine and associated with
platelet aggregates in the stenotic segment (demonstrated
by histologic and electron microscopic examination). These
observations support the conclusion that the flow re-
ductions were caused by platelet aggregation rather than
by fibrin deposition or vasospasm.
Twenty dogs were monitored for 1 hour after heparin
Coronary artery thrombosis has a major impact on morbidity
and mortality among patients with coronary artery disease.
Recent intraoperative (I) and angiographic (2-4) observa-
tions have demonstrated that a thrombus superimposed on
a stenotic lesion is usually responsible for obstruction of the
infarct-related vessel early in the course of acute myocardial
infarction. Furthermore, some cases of sudden death may
result from occlusive thrombosis of a large coronary artery
(5.6) or from lysis of a proximal coronary thrombus and
distal embolization of platelet aggregates (7,8).
Folts et aI. (9-12) have recently developed a canine model
of coronary thrombosis. They have demonstrated that a crit-
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administration and then assigned to a control (n = 7)
or nicergoline-treated (n = 13; 1 mg/kg intravenously)
group. In control dogs, cyclic reductions in flow contin-
ued unchanged for another hour, whereas in the treated
group they were markedly decreased in 1 dog and com·
pletely abolished in the other 12 dogs. Aspirin (30 mgl
kg intravenously) suppressed flow reductions in all con-
trol dogs, confirming the primary role of platelet ag-
gregation in the phenomenon.
This study provides a modified model of platelet-me-
diated thrombosis in stenosed coronary arteries. Fur-
thermore, the results indicate that nicergoline can ef-
fectively interfere with platelet function in vivo. The
potent antithrombotic activity exhibited by nicergoline
might enhance the therapeutic usefulness of this
vasodilator.
ical coronary stenosis can induce a gradual decrease of coro-
nary blood flow that is often followed by a spontaneous,
sudden return to the initial levels. They have also provided
compelling evidence that the transitory reductions in flow
are mediated by platelet aggregation rather than by vaso-
spasm or fibrin deposition. For example, the reductions in
flow are abolished by platelet inhibitors, including aspirin,
sulfinpyrazone, prostacyclin, ibuprofen and indomethacin,
but not by heparin, nitroglycerin or papaverine (9,10,12).
Furthermore, they have documented histologically the pres-
ence of a platelet thrombus in the stenotic vessel (9,10).
Similar models have been used by others (13-17). The
ability of a drug to suppress platelet-mediated thrombosis
in these experimental models might have important clinical
implications, because the role of platelets in the genesis of
human arterial thrombi is crucial (18,19).
Nicergoline is a new potent alpha-adrenergic antagonist
(20,21) relatively selective for postsynaptic alphal-receptors
(21,22). It has been used clinically as an antihypertensive
agent and a peripheral and cerebrovascular vasodilator (23).
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In addition to its vasodilator properties, nicergoline inter-
feres with platelet function (24-29). Because coronary ar-
tery disease is frequently associated with hypertension or
peripheral vascular disease, or both, the demonstration that
nicergoline can prevent coronary thrombosis might be of
considerable clinical interest. Our study was undertaken to
evaluate the effect of nicergoline on spontaneous coronary
thrombosis in a modified canine model derived from that
of Folts et al. (9). Preliminary experiments were performed
to ascertain that the observed cyclic reductions in coronary
flow were caused primarily by platelet aggregates.
Methods
Experimental Preparation
Forty-eight mongrel dogs of either sex, weighing 16 to
30 kg, were sedated with sodium thiamylal (10 mg/kg in-
travenously) and anesthetized 10 minutes later with alpha-
chloralose (70 mg/kg intravenously). Additional doses of
alpha-chloralose were administered during the experiment
as necessary to abolish the corneal reflex. The dogs were
intubated and ventilated with room air. The chest was opened
through the left fifth intercostal space and the heart was
suspended in a pericardial cradle. The proximal left circum-
flex coronary artery was isolated from the surrounding tis-
sues. The site of dissection was chosen to provide a long
segment (approximately 3 cm) free of ramifications; small
branches were tied whenever necessary.
Instrumentation. A Doppler ultrasonic flow probe was
placed around the artery at the proximal end of the isolated
segment (Fig. I). A 2-0 silk ligature was placed around the
vessel at the distal end of the dissected segment; because
of its distance from the flow probe, the ligature could be
used to produce temporary complete occlusions for mea-
surement of reactive hyperemia without altering the position
of the probe (Fig. 1). Polyethylene catheters for pressure
measurement were inserted into the left atrium through the
left atrial appendage and into the aorta through the left
carotid artery. Both catheters were connected to Statham
P23Db pressure transducers. A solid state pressure trans-
ducer (Konigsberg, model P-20) was positioned in the left
ventricular cavity through an incision in the left ventricular
apex. The first derivative of left ventricular pressure
(dP/dt) was obtained by electronic differentiation. Aortic
pressure, left ventricular pressure, dP/dt, left atrial pressure,
left circumflex coronary artery flow velocity and lead II of
the electrocardiogram were recorded continuously through-
out the study on an eight channel direct writing oscillograph
(Gould Brush System 2(0).
Production of coronary stenosis. After baseline re-
cordings, a stenosis was produced in the left circumflex
coronary artery in the following manner. The vessel was
plicated by passing a series of stitches (6-0 Prolene with
~ f Pressure
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Figure 1. Schematic representation of the experimental prepara-
tion. Ao = aorta; CFX = left circumflex coronary artery; LA =
left atrium; LAD = left anterior descending coronary artery; LV
= left ventricle; RA = right atrium.
nontraumatic needle) through its wall in the segment be-
tween the flow probe and the ligature, starting at the level
of the ligature (Fig. 1 and 2). The plication produced a 50
to 70% reduction of the vessel diameter. After each stitch,
the coronary artery was completely occluded for 20 seconds
to measUre reactive hyperemia. The plication was extended
proximally until the hyperemic response to these occlusions
was completely abolished. This was usually achieved with
plications 3 to 5 mm long. Of the 48 dogs instrumented,
34 showed cyclic reductions in left circumflex coronary
artery flow. All of these animals were given heparin (1,000
U/kg per h intravenously) to prevent deposition of fibrin at
the stenotic site. The cyclic reductions in flow were abol-
ished by heparin in 2 dogs and unaffected in the remaining
32. Twelve of these 32 dogs were used to validate the model
and 20 entered the nicergoline protocol.
Validation of the Model
Studies were carried out in 12 dogs to confirm that the
cyclic reductions in flow were caused primarily by platelet
aggregation rather than by fibrin deposition or coronary
spasm.
Histologic and ultrastructural studies. In seven dogs,
the thrombus was obtained for histologic and electron mi-
croscopic observation. The left circumflex coronary artery
flow was observed carefully and, when it reached a low
point, the artery was ligated distally and then proximally.
The vessel was immediately excised and immersed in either
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Figure 2. Low power view (hematoxylin-eosin x 180, reduced
by 23%) of a plicated circumflex coronary artery demonstrating
the spaces occupied by the suture material in vivo (asterisks).
(The stitches were removed after fixation to facilitate sectioning.)
Note that the suture material was not exposed in the stenotic lumen.
The lumen of the plicated portion of the vessel (right) is completely
obliterated.
buffered 10% formalin or buffered 3% glutaraldehyde, pH
7.3. The fixed tissue was cut into 5 mm segments and
embedded in paraffin. Serial sections of the entire segment
were stained with hematoxylin-eosin, Movat, periodic acid-
Schiff, phosphotungstic acid-hematoxylin and Verhoeff-van
Gieson stains.
Specimens for scanning electron microscopy were fixed
in buffered 3% glutaraldehyde, dehydrated through a graded
series up to absolute acetone, critical point dried in liquid
carbon dioxide and sputter-coated with gold-palladium 60/
40 ratio. Samples for transmission electron microscopy were
fixed in buffered 3% glutaraldehyde, postfixed in osmium
tetroxide, dehydrated and embedded in Spurr's medium ac-
cording to conventional procedures. All samples were ex-
amined on a JEOL 100C electron microscope equipped with
scanning attachment.
To determine whether platelet aggregates form in the
stenotic vessel in the absence of variations in flow, histologic
and ultrastructural studies were also carried out in 3 of the
13 dogs that failed to exhibit cyclic flow reductions after
production of the stenosis and in 2 of the 7 control dogs
after flow reductions had been eliminated by aspirin (see
later).
Experiments with vasodilators. A second group of five
dogs was observed for I hour and then treated with nitro-
glycerin (300 p,g intravenous bolus followed by an infusion
of 6 p,g/kg per min, n = 3) or nifedipine (100 p,g/kg in-
travenously over 5 minutes followed by an infusion of 3
p,g/kg per min, n = 2). All measured variables were mon-
itored for I hour after the start of treatment.
Nicergoline Protocol
Twenty dogs were used for the nicergoline protocol, which
consisted of two parts. The first part was a I hour obser-
vation period during which hemodynamic variables and the
electrocardiogram were continuously recorded to define a
baseline. Dogs were then assigned either to the control group
(n = 7), which received no intervention, or to the treated
group (n = 13), which was given nicergoline (l mg/kg
intravenously over 5 minutes). Nicergoline was dissolved
in water (concentration 10 mg/ml) with tartaric acid (3 mg/
ml). Tartaric acid has no known action on platelets. The
dogs were continuously monitored thoughout the subsequent
hour (the second part of the protocol). At the end of the
second part, the seven control dogs received acetylsalicylic
acid intravenously (30 mg/kg dissolved in 150 ml of normal
saline solution) and were observed for a third hour. At the
end of the experiment, the alpha-adrenergic blocking action
of nicergoline was assessed by determining the arterial pres-
sure response to intravenous injections of various doses of
phenylephrine in five control and eight nicergoline-treated
dogs. In the remaining two control dogs, the stenotic artery
was examined by light and electron micrograph as just
described.
Data analysis. The frequency of cyclic reductions in
flow in the stenotic artery was expressed as the number of
reductions per hour. The magnitude of cyclic reductions in
flow was defined as the average of all the sudden increments
in circumflex coronary artery flow during the observation
period. To minimize intra- and interobserver variability,
each increment was measured from the level immediately
preceding to the level immediately following the sudden
flow increase (Fig. 3).
All measured variables are reported as mean ± standard
error. Comparisons of means were performed with the two-
tailed Student's t test for paired or unpaired data as appropriate.
Results
Cyclic reductions in flow in the stenosed coronary artery
were characterized by a slowly decreasing flow followed by
a sudden return to control levels (Fig. 3 and 4). The sudden
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Figure 3. Cyclic reductions in flow in the stenosed circumflex
artery. The reductions in flow are associated with hemodynamic
changes suggestive of myocardial ischemia: decrease in left ven-
tricular systolic pressure, decrease in positive and negative first
derivative of left ventricular pressure (dP/dt) and increase in left
atrial pressure. For example, during the last reduction in flow
(right), left ventricular pressure decreases from 90 to 79 mm Hg,
peak positive dP/dt from 1,661 to 1,411 mm Hg/s and peak neg-
ative dP/dt from 1,161 to 936 mm Hg/s, whereas mean left atrial
pressure increases from 10.0 to 11.8 mm Hg. Arrows indicate
spontaneous restoration of blood flow after each reduction.
restorations of flow occurred either spontaneously or, if flow
declined to zero, after gentle shaking of the vessel. Marked
reductions in flow were associated with ST segment shifts
on the electrocardiogram (Fig. 4) and with hemodynamic
changes suggestive of myocardial ischemia (decrease in left
ventricular systolic pressure, decrease in positive and neg-
ative left ventricular dP/dt and increase in left atrial pressure
[Fig. 3]).
Validation of the Model
Histologic and ultrastructural studies. Histologic ex-
amination of the excised vessels showed the suture material
to be outside of the stenotic lumen, due to the fact that the
portion of the artery penetrated by the stitches was plicated
and, therefore, completely obliterated (Fig. 2). Conse-
quently, thrombus formation in this model cannot be as-
cribed to exposure of suture material in the lumen. Histo-
logic evidence of endothelial damage in the stenosed vessel
(for example, discontinuity of the internal elastical lamina)
was observed in 4 of the 12 dogs examined.
In all seven dogs that exhibited cyclic flow reductions,
histologic examination of the vessels that were ligated dur-
ing a episode of flow reduction revealed a luminal thrombus
in the stenotic segment (Fig. 5 and 6). Scanning and trans-
mission electron micrograph demonstrated the thrombus to
be made up mostly of platelet aggregates with small amounts
of fibrin and occasional white and red blood cells (Fig. 7).
In contrast, no platelet aggregates were observed in those
vessels that were excised from control dogs (n = 2) after
aspirin had abolished cyclic reductions in flow. Likewise,
no platelet thrombus was found in the stenosed artery of
dogs (n = 3) that failed to exhibit reductions in flow.
Effects of vasodilators on cyclic reductions in ftow. The
vasodilators nitroglycerin and nifedipine were administered
to evaluate the possibility that the cyclic reductions in flow
were caused by vasospasm. Neither nitroglycerin (n = 3)
nor nifedipine (n = 2) affected the frequency or the mag-
nitude of reductions in flow in the stenosed coronary artery,
despite administration of doses sufficient to decrease mean
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Figure 4. Cyclic reductions in flow in the
stenosed circumflex artery recorded at low
(A) and high (8) paper speed during the
same experiment. The two recordings are
not continuous, The ST segment is elevated
in lead II of the electrocardiogram (ECG)
during the phase of low flow (8), suggest-
ing ischemia in the circumflex artery (CFX)
territory; I minute later, after the thrombus
is dislodged and control flow restored (ar-
row), the ST segment returns to normal
levels, AoP = mean aortic pressure; LAP
= mean left atrial pressure; LV = left
ventricular; LVP = left ventricular pressure.
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arterial pressure by 22 ± 3 mm Hg (nitroglycerin) and by
30 ± 5 mm Hg (nifedipine).
Nicergoline Protocol
Hemodynamics (Table 1). In control dogs, heart rate,
mean arterial blood pressure and mean left atrial pressure
did not change significantly throughout the study, Although
mean circumflex coronary artery blood flow decreased slightly
after the stenosis was produced, the decrease did not achieve
statistical significance.
In nicergoline-treated dogs, none of the hemodynamic
variables changed significantly after the coronary artery was
stenosed. Treatment with nicergoline significantly lowered
heart rate ( - 51 ± 3 beats/min), mean arterial blood pres-
sure (- 32 ± I mm Hg) and mean circumflex coronary
artery blood flow (-13.4 ± 2.9 ml/min).
Cyclic reductions in flow. Control group (Table 2).
During the first part of the protocol, the frequency of cyclic
reductions in circumflex coronary artery flow in control dogs
averaged 16/h; the magnitude of these reductions averaged
14.5 ± 2.6 mllmin (corresponding to an average 33% de-
crease in blood flow from the levels observed between re-
ductions). Both the frequency and magnitude of cyclic re-
ductions in flow remained essentially unchanged during the
second part of the protocol. At the end of this part, cyclic
reductions in flow were completely abolished by aspirin in
every dog, indicating that they were caused primarily by
platelet aggregation.
Nicergoline-treated group (Fig. 8). Before treatment,
the frequency and magnitude of cyclic reductions in flow
were similar to those observed in the control group. Nicer-
goline completely abolished cyclic reductions in flow in all
but one dog within a few minutes after its administration
(p < 0.001 versus pretreatment frequency). In those dogs
in which nicergoline was administered during the phase of
decrease in flow, the flow reduction was promptly reversed.
In one dog, cyclic reductions in flow were not totally sup-
pressed; however, the frequency decreased by 68% and the
magnitude by 63%.
Alpha-agonist dose-response studies. Nicergoline ex-
hibited a potent alpha-adrenergic blocking activity. In the
five control dogs, the increase in mean arterial pressure in
response to 0.25,3.2, 16.0 and 32.0 p,g/kg of phenylephrine
averaged 4.7 ± 1.8, 25.6 ± 4.1, 72.8 ± 8.9 and 86.1 ±
13.2 mm Hg, respectively. In the eight treated animals that
were tested, no appreciable change in blood pressure was
observed with phenylephrine doses of 8 p,g/kg or less; doses
of 16 and 64 p,g/kg produced an increase in mean arterial
pressure of 5.7 ± 1.1 and 23.2 ± 5.0 mm Hg, respectively
(p < 0.01 versus corresponding values in control dogs).
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Figure S. Low power view (Verhoeff-van Gieson stain x 100,
reduced by 25%) of the stenotic segment of a coronary artery
excised during a reduction in flow. The lumen is almost entirely
occupied by a thrombus loosely attached to the intima (the internal
elastic lamina is the dark wavy line in the intima). The plication
of the vessel by the suture is visible on the right. The apparent
presence of a residual lumen in the plicated part is a postmortem
artifact due to retraction of tissues during fixation and to removal
of the stitches to facilitate sectioning of the specimen.
Discussion
Modeling considerations. The model of coronary
thrombosis used in this study is a modification of that orig-
inally described by Folts et al. (9) and employed by others
(15-17). Common to both models is the presence of a crit-
ical coronary stenosis that does not restrict basal flow, but
completely prevents the hyperemic response to total occlu-
sion. The main difference between the two models is that
Folts and coworkers produced the stenosis by encircling the
vessel with a plastic cylinder, whereas we plicated the ar-
terial wall with a suture. This technique was selected be-
cause it affords fine control of the severity of the stenosis,
as stitches can be added until the desired degree of obstruc-
tion is achieved. The suture also ensures a stable narrowing
Figure 6. Higher power view (periodic acid-Schiff stain x 250.
reduced by 26%) of a different area of the thrombus shown in
Figure 5. Note the fine granularity of the thrombus, which is
suggestive of platelet aggregates. Some white blood cells are pres-
ent at the periphery of the thrombus.
of the lumen, which cannot be modified by the movements
of the heart or by manipulations of the vessel (particularly
when transient complete occlusions are produced or the
thrombus is manually dislodged). Another difference from
previous models is that our animals were treated with hep-
arin. The rationale for this was to reduce fibrin deposition
and, thus, to maximize the contribution of platelets to throm-
bus foonation. This, in tum, might enhance the sensitivity
of the model to drugs that solely affect platelet function.
Role of endothelial damage. Although unequivocal his-
tologic evidence of endothelial damage was observed only
in 4 of the 12 dogs examined, the plication was probably
associated with some endothelial injury in all the dogs. This,
however, does not represent a drawback of the method.
Endothelial damage is invariably present even when coro-
nary stenosis is produced by an external constrictor, as in
JACC Vol. 3, No.6
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Figure 7. Ultrastructural examination
of the stenotic segment of circumflex
coronary artery excised during an ep-
isode of reduction in flow. Upper
panel. Scanning electron micrograph
(x 1,(00). An intraluminal thrombus
is attached to the endothelium (point-
ers). Arrows indicate red blood cells
within the thrombus. Middle panel,
Transmission electron micrograph
(x 7,(00). A mass of coalesced plate-
lets (right) is adjacent to the endo-
thelial surface (pointers). A smooth
muscle cell is visible below the en-
dothelium. Lower panel, Transmis-
sion electron micrograph ( x 7,(00) of
a different area of the same thrombus.
A red blood cell is surrounded by ac-
tivated platelets. All panels reduced by
34%.
the models of Folts et al. (10, II) and Aiken et al. (15, 16).
Such damage may be important in inducing platelet aggre-
gation (9-11) and appears to be necessary for thrombi to
fonn in a reproducible fashion (15,16). Furthennore, endo-
theliallesions are common in human atherosclerotic plaques
(30).
Platelet aggregation and cyclic flow reductions.
Theoretically, the cyclic reductions in flow observed in our
model might have been produced by platelet aggregation,
fibrin deposition, vasospasm or a combination of these fac-
tors. Several lines of evidence identify platelet aggregates
as the primary cause of the phenomenon. First, the cyclic
reductions in flow were consistently abolished by aspirin,
but not by massive doses of heparin, or doses of nitrogly-
cerin and nifedipine sufficient to produce marked hypoten-
sion. Second, the histologic and ultrastructural examination
of vessels ligated at a time when flow was at a low point
demonstrated that the cyclic reductions in flow were asso-
ciated with platelet plugs. The primary role of platelet ag-
gregates is further supported by their absence in vessels with
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Table 1. Hemodynamic Variables in Control and Nicergoline-Treated Dogs
Heart Rate Mean ABP Mean LAP Mean LCx Flow
(beats/min) (mm Hg) (mmHg) (mllmin)
C N C N C N C N
Before stenosis 160.1 ± 8.0 163.5 ± 9.1 94.1 ± 7.0 90.7 ± 6.2 5.1 ± 0.7 5.3 ± 0.6 50.3 ± 6.2 48.1 ± 5.8
After stenosis. 5 minutes 162.9 ± 7.8 168.8 ± 8.0 90.2 ± 6.5 91.3 ± 5.4 6.0 ± 0.9 6.2 ± 1.0 43.5 ± 7.8 39.9 ± 6.1
before treatment
30 minutes after treatment 161.5 ± 7.9 117.8 ± 4.1* 88.1 ± 6.7 59.2 ± 4.7* 6.2 ± 1.1 5.6 ± 1.1 40.1 ± 7.1 26.5 ± 4.0*
*p < 0.001 versus control subjects.
ABP = arterial blood pressure; C = control subjects; LAP = left atrial pressure; LCx = left circumflex coronary artery; N = nicergoline-treated.
Table 2. Frequency and Magnitude of Cyclic Reductions in
Flow in the Stenosed Artery in the Control Group
similar stenoses but obtained from dogs in which reductions
in flow either failed to occur or were abolished by aspirin.
Platelet aggregation in the stenotic segment might result
from the trauma to the endothelium, which exposes collagen
fibers, as well as from the turbulence of blood flow, which
damages platelets and red blood cells, causing release of
adenosine diphosphate (11). The lack of cyclic reductions
in flow in 14 of the 48 animals in which coronary stenosis
was produced may reflect an insufficient degree of endo-
thelial damage or a defect in platelet function that is present
in some dogs (31).
Platelet-inhibitory activity of nicergoline. Nicergoline
is a new semisynthetic ergoline derivative with potent alpha-
adrenergic blocking activity (20,21). This was confirmed in
our study, in which a marked degree of alpha-adrenergic
blockade was observed in treated animals. The potency of
nicergoline's alpha-adrenergic blocking activity is similar
to that of phentolamine (32). In contrast to phentolamine,
however, nicergoline is relatively selective for postsynaptic
alpha]-adrenergic receptors (21,22). Unlike other ergot al-
kaloids, it has no intrinsic alpha-adrenergic agonist activity
(20,21). The negative chronotropic action observed in our
treated group represents a unique feature of this alpha-ad-
renergic antagonist and appears to be mediated by an effect
on the central nervous system (21,33,34).
Previous reports (25,27-29) documented a potent platelet
inhibitory activity of nicergoline in vitro. The drug com-
pletely inhibits aggregation of human platelets by epineph-
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Figure 8. Effect of nicergoline (N) on frequency (A) and mag-
nitude (B) of cyclic reductions in flow (CRF) in the stenosed
circumflex coronary artery.
rine, adenosine diphosphate and collagen (25,27,28). If added
after platelets have been exposed to the aggregating agent,
nicergoline arrests the process of aggregation and causes
disaggregation (25,27). In vitro inhibition of platelets has
also been observed after oral administration of nicergoline
to patients with atherosclerosis (25,26). However, evidence
of efficacy of this drug in vivo is still lacking . Such evidence
is necessary because tests of platelet function in vitro may
not reflect the events occurring in the physiologic environ-
ment (35).
Our study demonstrates that nicergoline markedly inter-
feres with platelet function in vivo. The suppression of
cyclic reductions in flow documents inhibition of platelet
aggregation in the stenotic vessel. Furthermore, our obser-
vation that nicergoline promptly reversed the decrease in
flow occurring at the time when treatment was started sug-
gests that the drug acted to disaggregate recently formed
thrombi. This finding might be the in vivo equivalent of the
disaggregating properties observed in vitro (25,27).
o
Magnitude
(ml/min)
14.5 ± 2.6
13.1 ± 1.9
Frequency
(CRF/h)
o
16.0 ± 2.1
14.5 ± 1.5
First part of protocol
(first hour)
Second part of protocol
(second hour)
After aspirin
(third hour)
CRF = cyclic reductions in flow. Pr.-N PostoN Pre-N Post-N
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The mechanism by which nicergoline inhibits thrombosis
may be related to the alpha-adrenergic blocking activity of
the drug. Alpha-adrenergic receptors have been identified
in platelet membranes (36,37) and have been shown to me-
diate the aggregating response to epinephrine in vitro (38,39).
A role of these receptors in vivo is suggested by the recent
report (II) that the alpha-adrenergic antagonist phentola-
mine reduces cyclic reductions in flow in a model similar
to that employed in the present study. The effect of nicer-
goline on thrombosis could also reflect extra-adrenergic ac-
tions. Nicergoline induces platelet ultrastructural changes
(such as depolymerization of microtubules [27]) and inhi-
bition of platelet phospholipase (28). This latter action pre-
vents liberation of arachidonic acid from membrane phos-
pholipids and, thus, production of thromboxane A2 (28).
Clinical implications. Value of experimental model. In
this study, we present a canine model of platelet-mediated
thrombosis in stenotic coronary arteries. Extrapolation of
our experimental data to human beings must be made with
caution, because the events leading to thrombosis in an
atherosclerotic vessel may differ from those taking place in
a traumatized, previously normal artery. Nevertheless, be-
cause platelets play a critical role in the formation of oc-
clusive coronary thrombi in human beings (18,19,40), the
basic mechanism causing coronary obstruction appears to
be similar in the experimental and clinical settings. Ac-
cordingly, this canine model might be useful for the study
of the mechanisms that lead to thrombus formation at the
site of an atherosclerotic lesion, as well as for the assessment
of platelet-active agents of potential therapeutic value.
Role ofnicergoline. Our investigation also demonstrates
that nicergoline completely prevents thrombosis in stenosed
canine cronary arteries. Clinical studies are obviously nec-
essary before these results can be applied to human beings;
for example, it is difficult to correlate the dosage of nicer-
goline in our canine model with that used in patients. Clin-
ical trials have employed doses ranging from 30 to 60 mg
orally (25) and from 5 to 20 mg intravenously (33). Al-
though in relation to body weight these doses are lower than
ours (I mg/kg intravenously), the pharmacokinetics of ni-
cergoline have not been defined in human subjects or in
dogs and, consequently, a valid comparison of experimental
and clinical dosages is not possible. However, even oral
doses of nicergoline of 30 mg are sufficient to inhibit human
platelets in vitro (25,26). On the basis of these results and
of our findings, it seems reasonable to suggest a potential
antithrombotic action of nicergoline in human subjects. To
date, this drug has been used for its vasodilator properties
in the treatment of hypertension (23), peripheral vascular
disease (23) and congestive heart failure (33,34). The ability
of nicergoline to prevent arterial thrombosis would be of
benefit in these syndromes and, more generally, in athero-
sclerotic cardiovascular disease.
An additional consideration is that nicergoline differs
from many platelet-active compounds in that it inhibits both
platelet aggregation and platelet adhesion to collagen, elas-
tin and endothelial cells (29). Because the interaction be-
tween platelets and these elements of the arterial wall might
play an important role in the pathogenesis of atherosclerosis
(30,41), it is theoretically conceivable that nicergoline might
interfere with the progression of this disorder. Therefore,
investigation of the effects of nicergoline in patients with
atherosclerotic cardiovascular disease seems warranted.
We thank Iacques Chelly, MD. for useful advice. Specia Laboratories.
Paris, France for supplying nicergoline and Carolyn M. Ferrante and Kathryn
Schmeltekopf for providing expert secretarial assistance.
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